That's on top of about 150 RIFs that were also part of that center. If you look at the drug center, they lost about a third of the reviewers that review breast and gynecological cancer products. They lost more than half of the group that reviews malignant heme products. They've seen 473 departures of medical reviewers, voluntary departures, on top of about 600 RIFs. That's more than 20% at center. (07:56–08:02)
CLAIM
Asserts that more than half of the reviewers for malignant heme products have left.
This is an excerpt from a raw transcript. The assertions have not been audited or verified. Tap the video to view the source footage and understand the context.
